Podcasts

Episode 58 | Prof Anna Nowak: A Journey from Oncology Lab to Leadership

In this episode, we welcome Prof Anna Nowak, a renowned medical oncologist, clinical trialist, and tumour immunology researcher.

Episode Summary

In this episode of Conversations in Lung Cancer Research, host A/Prof Mel Moore interviews Prof Anna Nowak, a renowned medical oncologist, clinical trialist, and tumour immunology researcher. We learn of Anna’s early aspirations influenced by her family and mentors, her educational and professional trajectory, and her transition to a leadership role as Deputy Vice Chancellor at the University of Western Australia. Anna shares insights on the challenges and rewards of juggling clinical practice with research, her contributions to mesothelioma studies, involvement in the DREAM and DREAM3R trials, and her role in mentoring the next generation of oncologists.

 Show Guest

  • Prof Anna Nowak, Deputy Chancellor (Research), University of Western Australia, Fellow, Australian Academy of Health and Medical Sciences, on-Executive Director, Cancer Council Western Australia, Advisory Council Member, Cancer Australia, President-Elect,  International Mesothelioma Interest Group.

 Show Links

Lung cancer podcast with Prof Anna Nowak

Play Episode 58 | Prof Anna Nowak: A Journey from Oncology Lab to Leadership

More Podcasts

Host A/Prof Steven Kao is joined by A/Prof Venessa Chin and Dr Ben Kong,
Host A/Prof Mel Moore interviews Prof Zarnie Lwin OAM, University of Queensland; Medical Oncologist at Royal Brisbane and Women’s Hospital and The Prince Charles Hospital.
A/Prof Gavin Wright sits down with a multidisciplinary panel of experts to tackle the critical and complex issue of smoking-related stigma in lung cancer.
Host A/Prof Mel Moore interviews Dr Jazmin Eckhaus, a practising surgeon in the subspecialty of thoracic surgery.
Host A/Prof Adnan Nagrial leads a panel discussing the clinical implications of the broad PBS listing of ipilimumab and nivolumab in Australia.
Host A/Prof Deme Karikios leads a panel discussion focusing on the recent, groundbreaking broad PBS listing of certain immunotherapy agents in Australia.